Table 1.

Cost savings per SVR with SOF/SMV: Base case and sensitivity analyses

Scenario	Cost per SVR (SOF/RBV)	Cost per SVR (SOF/SMV)	Cost savings per SVR with SOF/SMV
Base case	$262,046	$170,456	$91,590
Sensitivity Analyses
Disease characteristics
Advanced fibrosis (Metavir stage F3/F4) only	$284,407	$186,968	$97,439
Genotype 1/subtype A with Q80K polymorphism only (all fibrosis stages)	$262,046	$188,856	$73,190
SVR rates*
Low SOF/SMV; high SOF/RBV	$221,156	$175,450	$45,706
High SOF/SMV; low SOF/RBV	$312,160	$162,404	$149,756
High SOF/SMV; base case SOF/RBV	$262,046	$162,404	$99,642
Low SOF/LDV	$265,425	$170,494	$94,931
Tolerability
Doubled likelihood of adverse events during treatment	$262,171	$170,463	$91,708
Retreatment
Cost of SOF/LDV rescue therapy set at $0 per treatment	$194,347	$165,432	$28,915
Decreased proportion retreated after initial failure*	$261,081	$169,965	$91,116

^*See Table 4 for low and high SVR thresholds for each drug regimen, and for low threshold for proportion retreated after initial failure.

F3/F4 = Metavir fibrosis stages 3 and 4; LDV = ledipasvir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; Q80K = a naturally occurring polymorphism found in up to 47% of HCV genotype 1/subtype A infected individuals and less commonly in those with HCV genotype 1/subtype B; the presence of this polymorphism has been associated with lower SVR rates in subjects treated with simeprevir in combination with other drugs.